Small Molecule drug treatment is one of the main approaches in treating cancer. Until recent years, chemotherapy was the only approach to treat cancer; with its biggest inability is to distinguish between cancer cells and normal cells, thus resulting in significant toxicity and side effects.
In last two decades, there has been a tremendous shift in cancer treatment, from broad-spectrum cytotoxic drugs to targeted therapies. Unlike traditional chemotherapy drugs, targeted drugs can specifically target cancer cells but spare normal cells, hence having high potency and low toxicity.
Cancer Targeted Therapies can be roughly classified into two categories: Small Molecules and Macromolecules/ Biologics (e.g., monoclonal antibodies, polypeptides, antibody–drug conjugates, and nucleic acids).
To date, there are a nearly 100 anti-cancer targeted small molecules approved in the United States and China, with large number under clinical development, targeting kinases, epigenetic regulatory proteins, DNA damage repair enzymes, and proteasomes.
Following are the series of articles which provides the latest updates and insights on Targeted Small Molecule Cancer Drug Development.
updated.. easy.. precise... complete...
Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.
LEARN MORE »
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.
Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.